Healthcare Innovation
-
A Trade Agreement Doesn’t Create a Corridor
The UK and Gulf are removing barriers to trade. The bigger opportunity is what we choose to build between them. On 20 May 2026, after years of negotiation, Britain and the six Gulf states announced that they had reached agreement on a new free trade deal. Somewhere inside that agreement are numbers that will make…
Birmingham healthcare innovation, Birmingham life sciences, cross-border healthcare, GCC healthcare, GCC market entry, Gulf healthcare, Gulf investment UK, Harun Rabbani, health and life sciences corridor, health innovation, healthcare ecosystems, Healthcare Innovation, Healthcare Investment, healthcare trade, international business trust, international healthcare partnerships, inward investment West Midlands, life sciences investment, MedTech Investment, MedTech market entry, NHS Innovation, PHTA Birmingham, Precilium, Precision Health Technologies Accelerator, Saudi Arabia healthcare, Saudi Arabia market entry, Saudi Arabia MedTech, Signal Before Scale, trusted business relationships, UAE healthcare, UK life sciences, UK-GCC free trade agreement, UK-GCC investment, UK-GCC relations, UK-GCC trade deal, UK-Gulf healthcare, West Midlands life sciences, West Midlands MedTech
-
The NHS Doesn’t Buy Technology
Here’s a curious thought. Imagine inventing a better parachute. You spend years proving it works. It’s safer, lighter and easier to use. Every independent test says it’s an improvement…but nobody buys it. Most people would conclude there must be something wrong with the parachute. What if there wasn’t? During my conversation with Vee Mapunde, Co-Director of…
Board Leadership, Change Management, Clinical Engineering, Clinical Governance, Clinical Innovation, Commercialisation, Decision Making, Executive Leadership, Governance, Health Systems, Health Technologies, Health Technology, Healthcare Adoption, Healthcare Commercialisation, Healthcare Ecosystem, Healthcare Innovation, Healthcare Investment, Healthcare Leadership, Healthcare Strategy, Healthcare Systems, Healthcare Transformation, HealthTech, HealthTech Founders, Implementation Science, Information Governance, Innovation Adoption, Innovation Ecosystem, leadership, Leadership Architecture, Medical Device Adoption, Medical Devices, Medical Technology, MedTech, MedTech Founders, NHS, NHS Innovation, NHS Procurement, NIHR, Organisational Change, Organisational Coherence, Organisational Complexity, Organisational Design, Organisational Leadership, Patient Care, Patient Outcomes, Precilium, Procurement, Scale-up, Scaling Companies, Series A, Series B, Series C, Signal Before Scale, Signal Before Scale Conversations, Systems Thinking, Technology Adoption, Translational Research, Vee Mapunde, Venture Capital, Workflow Design
-
The Moment Optionality Begins to Narrow in MedTech Scale-Ups
If you have not yet watched this week’s Signal Before Scale episode on Olive AI and invisible momentum collapse in MedTech, I would strongly encourage you to begin there. The video explores a strange phenomenon increasingly visible across healthcare technology: How organisations can appear externally successful while internally becoming progressively heavier, slower, and more fragile.…
-
Why Boards Often Realise the Value of a CMO Too Late
Clinical leadership in MedTech is rarely treated as a strategic variable at the start. In early stages, it often appears procedural. A role associated with compliance, trials, and regulatory navigation. Certainly treated as important but not always central to valuation. That perception tends to change when the inevitable pressure mounts. As scale approaches, clinical judgement…
